118 related articles for article (PubMed ID: 16920033)
1. Assays to evaluate the genotoxicity of retroviral vectors.
Nienhuis AW
Mol Ther; 2006 Oct; 14(4):459-60. PubMed ID: 16920033
[No Abstract] [Full Text] [Related]
2. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
3. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
4. Is retroviral gene marking too dangerous to use?
Brenner MK; Heslop HE
Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
[No Abstract] [Full Text] [Related]
5. Genotoxicity in gene therapy: an account of vector integration and designer nucleases.
Bohne J; Cathomen T
Curr Opin Mol Ther; 2008 Jun; 10(3):214-23. PubMed ID: 18535928
[TBL] [Abstract][Full Text] [Related]
6. Target and non-target effects of retrovirus vectors used for gene therapy and vaccination.
Onions D
Dev Biol Stand; 1995; 84():59-74. PubMed ID: 7796969
[No Abstract] [Full Text] [Related]
7. Bubble babies and bathwater.
Nat Biotechnol; 2002 Nov; 20(11):1063. PubMed ID: 12410236
[No Abstract] [Full Text] [Related]
8. Basic research tries to decrease the risks of translational medicine.
Cavazzana-Calvo M
Gene Ther; 2009 Mar; 16(3):309-10. PubMed ID: 19279646
[No Abstract] [Full Text] [Related]
9. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
Kaiser J
Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
[No Abstract] [Full Text] [Related]
10. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B; Roeder I
Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
[TBL] [Abstract][Full Text] [Related]
11. The use and development of retroviral vectors to deliver cytokine genes for cancer therapy.
Fong TC; Sauter SL; Ibañez CE; Sheridan PL; Jolly DJ
Crit Rev Ther Drug Carrier Syst; 2000; 17(1):1-60. PubMed ID: 10755210
[TBL] [Abstract][Full Text] [Related]
12. Retroviral bicistronic vectors.
Pfützner W
Drug News Perspect; 2008 Nov; 21(9):473-80. PubMed ID: 19180265
[TBL] [Abstract][Full Text] [Related]
13. Retroviral infection.
Bowen RA
Methods Mol Biol; 2002; 180():83-9. PubMed ID: 11873661
[No Abstract] [Full Text] [Related]
14. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
15. The importance of being RCR.
Günzburg WH
Curr Opin Mol Ther; 2001 Oct; 3(5):437-8. PubMed ID: 11699887
[No Abstract] [Full Text] [Related]
16. Lineage analysis using retroviral vectors.
Cepko CL; Ryder E; Austin C; Golden J; Fields-Berry S; Lin J
Methods; 1998 Apr; 14(4):393-406. PubMed ID: 9608510
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer to the rodent embryo by retroviral vectors.
Luskin MB
Methods Mol Biol; 2008; 461():201-20. PubMed ID: 19030798
[No Abstract] [Full Text] [Related]
18. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
[TBL] [Abstract][Full Text] [Related]
19. Retroviral shuttle vectors as a tool for the study of mutational specificity (base substitution/deletion/mutational hotspot).
Ashman CR
Mutat Res; 1989; 220(2-3):143-9. PubMed ID: 2927422
[TBL] [Abstract][Full Text] [Related]
20. Release testing of retroviral vectors and gene-modified cells.
Nordling D; Kaiser A; Reeves L
Methods Mol Biol; 2009; 506():265-79. PubMed ID: 19110632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
